it appears the question of efficacy for SB is nearly confirmed by fda this month. so the next market risk is pipeline of new platforms, which is robust. if you believe in those platforms - than the only question is which (USA) Pharma company is the natural acquirer. and more importantly for shareholders: is it a strategic or economic multiple paid. I believe the terminal value is 3-5 aud per share in the next 5 years.
BOT - Anything but charting, page-5737
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $771.7K | 2.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 198576 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 135392 | 18 |
View Market Depth
| Last trade - 13.29pm 09/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |